Syntho acquires MOSTLY AI brand and wins ITEA Award of Excellence

Amsterdam-based company Syntho, founded in 2020 and specialising in synthetic test data, has reached two new milestones. On 9 June 2026, the company announced the acquisition of the MOSTLY AI brand. In addition, Syntho had previously won the ITEA Award of Excellence for Business Impact for its contribution to the European healthcare project IWISH.

The two developments are unrelated to each other but both touch on the same core theme: synthetic data as an alternative to real production data, enabling organisations to test, train and analyse safely without using privacy-sensitive information.

MOSTLY AI brand continued under Syntho

Austrian company MOSTLY AI GmbH ceased its independent operations in March 2026. Syntho subsequently acquired the brand and its associated product. The brand will continue under the name MOSTLY AI, powered by Syntho.

Wim Kees Janssen, CEO and co-founder of Syntho, stated he was pleased to welcome the brand into the Syntho ecosystem. Tobias Hann, formerly of MOSTLY AI, indicated he was satisfied that the brand had found a home at Syntho.

Through the acquisition, Syntho aims to further expand its platform. The company combines multiple approaches to generating synthetic data: via AI models, via synthetic data masking, and via rule-based methods. The rationale behind this approach is that a single unified platform can serve a range of needs, from software development to compliance applications.

IWISH project improved operating theatre performance

On 16 September 2025, Syntho received the ITEA Award of Excellence for Business Impact. The award recognised the company's contribution to the IWISH project, a European research project on more efficient healthcare processes, which ran from March 2022 to February 2025.

European hospitals are estimated to lose around €9 billion per year due to inefficient use of operating theatres. Within IWISH, partners worked on solutions to address this. One of the measured outcomes was a 36% improvement in the proportion of surgeries ending on time.

Within the project, Syntho developed the Syntho Engine, a scalable platform for generating synthetic data for clinical applications. The platform was validated against real clinical datasets. The performance gap compared to real data was 0.6% on machine learning tasks, meaning that AI models trained on synthetic data perform comparably to models trained on real patient data. Whereas collecting and accessing clinical data normally takes weeks or months, the Syntho Engine can deliver synthetic training data almost immediately.

Partners in the project included Leiden University Medical Center, TU Delft, Almende and Philips from the Netherlands, Workforce Optimizer from Singapore, and several Turkish organisations including ARD GROUP and MIA Teknoloji. Funding came from the Netherlands Enterprise Agency (RVO), Enterprise Singapore, and the Turkish research agency TÜBİTAK.

Syntho grew from three to fifteen employees during the IWISH project.

Significance for the Dutch AI scene

Syntho demonstrates how a young Dutch AI company can work simultaneously on scale and brand recognition through publicly funded research and commercial acquisitions. Participation in IWISH yielded both validation on clinical datasets and a growing team; the MOSTLY AI acquisition adds a European brand with an existing user base to the portfolio.

For other founders and investors in the Dutch AI scene, it is notable that Syntho was able to acquire the customer base and brand value of a European competitor after it had ceased its independent operations. That kind of consolidation, whereby a relatively small synthetic data market contracts around a handful of players, is a pattern also emerging in adjacent AI sub-markets.